Gilead Q3 base business sales up 16%, HIV sales up 18% with Biktarvy at all-time high

Gilead Sciences reported a strong third quarter with base business sales up 16% year-over-year, driven by growth in HIV products, Trodelvy and Livdelzi. HIV sales grew 18% year-over-year, with Biktarvy reaching an all-time high in U.S. sales.

Detected & updated continuously · Source: Nebula